Verastem (VSTM) Stock Forecast & Price Target

Compare

1,959 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

VSTM Analyst Ratings

Strong Buy

5 Buy

0 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Verastem

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

VSTM Stock 12 Month Forecast

Average Price Target

$15.60

▲(129.75% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Verastem in the last 3 months. The average price target is $15.60 with a high forecast of $20.00 and a low forecast of $14.00. The average price target represents a 129.75% change from the last price of $6.79.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","12":"$12","21":"$21","7.5":"$7.5","16.5":"$16.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,7.5,12,16.5,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.72,8.664615384615384,9.60923076923077,10.553846153846154,11.49846153846154,12.443076923076923,13.387692307692308,14.332307692307694,15.276923076923078,16.22153846153846,17.166153846153847,18.110769230769233,19.055384615384618,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.72,8.326153846153845,8.932307692307692,9.538461538461538,10.144615384615385,10.75076923076923,11.356923076923078,11.963076923076922,12.569230769230769,13.175384615384615,13.78153846153846,14.387692307692308,14.993846153846153,{"y":15.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.72,8.203076923076923,8.686153846153847,9.169230769230769,9.652307692307692,10.135384615384615,10.618461538461538,11.10153846153846,11.584615384615384,12.067692307692308,12.55076923076923,13.033846153846152,13.516923076923078,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.17,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.08,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.6,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.82,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.43,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.02,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.29,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.08,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.22,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.45,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.34,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.72,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$20.00

Average Price Target$15.60

Lowest Price Target$14.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Graig Suvannavejh

Mizuho Securities

$15

Buy

120.91%

Upside

Reiterated

01/13/26

Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (NYSE: EW), Verastem (NASDAQ: VSTM) and Armata Pharmaceuticals (NYSE MKT: ARMP)

Leonid Timashev

RBC Capital

$14→$15

Buy

120.91%

Upside

Reiterated

01/08/26

Analysts Are Bullish on These Healthcare Stocks: SOPHiA GENETICS (SOPH), Verastem (VSTM)

Michael Schmidt

Guggenheim

$14

Buy

106.19%

Upside

Reiterated

12/30/25

Verastem ending RAMP 203 study doesn't impact thesis, says GuggenheimVerastem ending RAMP 203 study doesn't impact thesis, says Guggenheim

Sean Lee CFA

H.C. Wainwright

$14

Buy

106.19%

Upside

Reiterated

11/05/25

H.C. Wainwright Remains a Buy on Verastem (VSTM)

Justin Zelin

BTIG

$20

Buy

194.55%

Upside

Reiterated

11/04/25

Verastem's Strong Commercial Performance and Growth Potential Reinforce Buy Rating

Eric Schmidt FCA

Cantor Fitzgerald

Buy

―

Initiated

10/16/25

Verastem assumed with an Overweight at Cantor FitzgeraldVerastem assumed with an Overweight at Cantor Fitzgerald

Kalpit Patel

Wolfe Research

$16

Buy

135.64%

Upside

Reiterated

10/10/25

B. Riley Securities Reaffirms Their Buy Rating on Verastem (VSTM)

Kelly Shi

Jefferies

$19

Buy

179.82%

Upside

Reiterated

06/04/25

Verastem's Strategic Growth and Promising Clinical Data Drive Buy Rating

James Molloy

Alliance Global Partners

$14

Buy

106.19%

Upside

Reiterated

05/14/25

Alliance Global Partners Sticks to Its Buy Rating for Verastem (VSTM)

Gregory Renza

Truist Financial

$16

Buy

135.64%

Upside

Reiterated

05/13/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Sean Lee

Citi

$7→$10

Buy

47.28%

Upside

Reiterated

03/24/25

Verastem's Promising Financial Outlook and Strategic Advancements Drive Buy Rating

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Graig Suvannavejh

Mizuho Securities

$15

Buy

120.91%

Upside

Reiterated

01/13/26

Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (NYSE: EW), Verastem (NASDAQ: VSTM) and Armata Pharmaceuticals (NYSE MKT: ARMP)

Leonid Timashev

RBC Capital

$14→$15

Buy

120.91%

Upside

Reiterated

01/08/26

Analysts Are Bullish on These Healthcare Stocks: SOPHiA GENETICS (SOPH), Verastem (VSTM)

Michael Schmidt

Guggenheim

$14

Buy

106.19%

Upside

Reiterated

12/30/25

Verastem ending RAMP 203 study doesn't impact thesis, says GuggenheimVerastem ending RAMP 203 study doesn't impact thesis, says Guggenheim

Sean Lee CFA

H.C. Wainwright

$14

Buy

106.19%

Upside

Reiterated

11/05/25

H.C. Wainwright Remains a Buy on Verastem (VSTM)

Justin Zelin

BTIG

$20

Buy

194.55%

Upside

Reiterated

11/04/25

Verastem's Strong Commercial Performance and Growth Potential Reinforce Buy Rating

Eric Schmidt FCA

Cantor Fitzgerald

Buy

―

Initiated

10/16/25

Verastem assumed with an Overweight at Cantor FitzgeraldVerastem assumed with an Overweight at Cantor Fitzgerald

Kalpit Patel

Wolfe Research

$16

Buy

135.64%

Upside

Reiterated

10/10/25

B. Riley Securities Reaffirms Their Buy Rating on Verastem (VSTM)

Kelly Shi

Jefferies

$19

Buy

179.82%

Upside

Reiterated

06/04/25

Verastem's Strategic Growth and Promising Clinical Data Drive Buy Rating

James Molloy

Alliance Global Partners

$14

Buy

106.19%

Upside

Reiterated

05/14/25

Alliance Global Partners Sticks to Its Buy Rating for Verastem (VSTM)

Gregory Renza

Truist Financial

$16

Buy

135.64%

Upside

Reiterated

05/13/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Sean Lee

Citi

$7→$10

Buy

47.28%

Upside

Reiterated

03/24/25

Verastem's Promising Financial Outlook and Strategic Advancements Drive Buy Rating

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Verastem

3 Months

xxx

Success Rate

8/15 ratings generated profit

Average Return

+12.66%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 53.33% of your transactions generating a profit, with an average return of +12.66% per trade.

1 Year

Justin ZelinBTIG

Success Rate

8/15 ratings generated profit

Average Return

+24.11%

reiterated a buy rating 2 months ago

Copying Justin Zelin's trades and holding each position for 1 Year would result in 53.33% of your transactions generating a profit, with an average return of +24.11% per trade.

2 Years

xxx

Success Rate

9/15 ratings generated profit

Average Return

+29.37%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 60.00% of your transactions generating a profit, with an average return of +29.37% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VSTM Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, VSTM has received 8 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. VSTM average Analyst price target in the past 3 months is 15.60.

Each month's total comprises the sum of three months' worth of ratings.

VSTM Financial Forecast

VSTM Earnings Forecast

Next quarter’s earnings estimate for VSTM is -$0.52 with a range of -$0.67 to -$0.42. The previous quarter’s EPS was -$1.35. VSTM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year VSTM has Performed in-line its overall industry.

VSTM Sales Forecast

Next quarter’s sales forecast for VSTM is $16.59M with a range of $11.62M to $22.85M. The previous quarter’s sales results were $11.24M. VSTM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year VSTM has Performed in-line its overall industry.

VSTM Stock Forecast FAQ

What is VSTM’s average 12-month price target, according to analysts?

Based on analyst ratings, Verastem’s 12-month average price target is 15.60.

What is VSTM’s upside potential, based on the analysts’ average price target?

Verastem has 129.75% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is VSTM a Buy, Sell or Hold?

Verastem has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.

What is Verastem’s price target?

The average price target for Verastem is 15.60. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $20.00 ,the lowest forecast is $14.00. The average price target represents 129.75% Increase from the current price of $6.79.

What do analysts say about Verastem?

Verastem’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of VSTM?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Verastem (VSTM) Stock Forecast & Price Target

VSTM Analyst Ratings

VSTM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Verastem

VSTM Analyst Recommendation Trends

VSTM Financial Forecast

VSTM Earnings Forecast

VSTM Sales Forecast

VSTM Stock Forecast FAQ

Detailed List of Analyst Forecasts